Published January 11, 2023 | Version v1
Journal article

Optimal timing of a γH2AX analysis to predict cellular lethal damage in cultured tumor cell lines after exposure to diagnostic and therapeutic radiation doses

  • 1. Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi (Japan)
  • 2. Narita Memorial Proton Center, Toyohashi, Aichi (Japan)
  • 3. Gunma University Heavy Ion Medical Center, Maebashi, Gunma (Japan)
  • 4. Department of Radiation Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi (Japan)

Description

Phosphorylated H2AX (γH2AX) is a sensitive biomarker of DNA double-strand breaks (DSBs). To assess the adverse effects of low-dose radiation (<50 mGy), γH2AX levels have typically been measured in human lymphocytes within 30 min of computed tomography (CT) examinations. However, in the presence of DSB repair, it remains unclear whether γH2AX levels within 30 min of irradiation completely reflect biological effects. Therefore, we investigated the optimal timing of a γH2AX analysis to predict the cell-surviving fraction (SF). Three tumor cell lines were irradiated at different X-ray doses (10-4000 mGy), and the relationships between SF and relative γH2AX levels were investigated 15 min and 2, 6, 12 and 24 h after irradiation. Data were analyzed for high-dose (0-4000 mGy) and low-dose (0-500 mGy) ranges. Correlations were observed between SF and the relative number of γH2AX foci/nucleus at 12 h only (R2 = 0.68, P = 0.001 after high doses; R2 = 0.37, P = 0.016 after low doses). The relative intensity of γH2AX correlated with SF 15 min to 12 h after high doses and 2 to 12 h after low doses, with the maximum R2 values being observed 2 h after high doses (R2 = 0.89, P < 0.001) and 12 h after low doses (R2 = 0.65, P < 0.001). Collectively, cellular lethal damage in tumor cells was more accurately estimated with residual DSBs 12 h after low-dose (10-500 mGy) irradiation. These results may contribute to determination of the optimal timing of biodosimetric analyses using γH2AX in future studies.

Availability note (English)

Available from http://dx.doi.org/10.1093/jrr/rrac096; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036098

Additional details

Publishing Information

Journal Title
Journal of Radiation Research
Journal Volume
64
Journal Issue
2
Journal Page Range
p. 317-327
ISSN
0449-3060

Optional Information

Copyright
Copyright (c) The Author(s) 2023. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.
Notes
PMCID: PMC10036098; PMID: 36634337; PMID: 36634337; PUBLISHER-ID: rrac096; OAI: oai:pubmedcentral.nih.gov:10036098